Background The efficacy of noninvasive ventilation (NIV) in acute exacerbation of pulmonary tuberculosis sequelae has not been fully studied. Methods We retrospectively reviewed 58 patients with acute exacerbation of pulmonary tuberculosis sequelae who were admitted to Tosei General Hospital and treated with NIV over a 9-year period.
Introduction
Since Meduri et al first reported the usefulness of noninvasive ventilation (NIV) to avoid endotracheal intubation in patients with acute respiratory failure in 1989 (1), a number of prospective randomized controlled trials of NIV have been published, especially for patients with acute exacerbation of COPD (2) (3) (4) (5) (6) (7) (8) (9) . Most of them have documented benefit from the addition of NIV: a decrease in the total duration of mechanical ventilation (invasive and noninvasive), and a shorter hospital stay. However, little is known about the efficacy of NIV for acute exacerbation of pulmonary tuberculosis sequelae (TB-seq) because of the small number of patients in the USA and other western countries.
In Japan, pulmonary tuberculosis is still a significant disease, from which more than 2,000 people a year die. The incidence of all forms of tuberculosis is about 20.0 per 100,000 population in Japan, which is a high rate compared with Europe and the United States. In patients with tuberculosis, cicatrization of a broad lesion of the lungs results in chronic respiratory failure after several years or more and the sequelae remains important today as a cause of chronic respiratory failure. In addition, treatment by surgical collapse, especially thoracoplasty, may cause a restrictive pulmonary disorder as a result of thoracic deformity.
Therefore, we conducted this study to evaluate the efficacy of NIV in patients with acute exacerbation of TB-seq, and to identify predictive factors for the success or failure of this technique. study and did not require the patients' approval or informed consent for the retrospective review of their records. We retrospectively reviewed 58 patients with acute exacerbation of TB-seq who were admitted to Tosei General Hospital and treated with NIV during the period from March 3, 1996 to August 30, 2005. The diagnosis of TB-seq was based on the clinical history, physical examination and chest X-ray. As recommended by Mehta and Hill (10) , those patients who presented with a recent onset of symptoms of acute respiratory distress (dyspnea increased over usual and respiratory rate (RR) >24, accessory muscle use, paradoxical breathing) and gas exchange abnormalities (PaCO2>45 mmHg and pH< 7.35) were eligible for inclusion in the study. Patients with any of the following were excluded from the study: respiratory arrest, medical instability (hypotensive shock, uncontrolled cardiac ischemia or arrhythmias), inability to protect the airway (impaired cough or swallowing mechanism), excessive secretions, agitated or uncooperative mental state, or facial trauma, burns, surgery, or anatomic abnormalities interfering with mask fit. If a patient had more than one episode that met the criteria, only the data from the first episode were included in the study. Informed consent for NIV was obtained from all patients.
Noninvasive ventilation protocol
All patients received mechanical ventilation using BiPAP Vision (Respironics, Inc., Murrysville, PA) and the ventilator was set in the spontaneous/timed mode. The initial inspiratory positive airway pressure (IPAP) was set at 8 cmH2O and IPAP levels were raised by 2 cmH2O in order to keep pH at >7.3, but IPAP levels did not exceed 24 cmH2O. Expiratory positive airway pressure (EPAP) was started at a level of 4 cmH2O. The FiO2 level was set to maintain oxygen saturation at greater than 90 percent. Sedation was never used for any of the patients during NIV therapy. Patients were closely monitored, with frequent recording of vital signs in accordance with standard practice, including continuous ECG and oximetric monitoring. When a patient's respiratory status had improved, weaning was attempted either by gradual reduction in the levels of ventilatory support or by initiating brief periods without NIV.
Success of NIV was defined as a withdrawal of NIV without the need for further assisted ventilation for an additional 72 hours. Failure was defined as the need for conventional intubation or death during NIV with a do-not-intubate (DNI) order.
Statistical analysis
Results are expressed as mean ± SD. A one-way analysis of variance with repeated measures was used to compare arterial blood gases before and after the institution of NIV therapy. The differences in the parameters between the success group and failure group were compared using a nonparametric unpaired test (Mann-Whitney U-test) and Fisher's exact probability test. p<0.05 was considered to be statistically significant.
Results

Patient characteristics
Fifty-eight patients with acute exacerbation of TB-seq were enrolled in the study: 39 men and 19 women with a mean age of 76 years (range, 54 to 90). Causes of acute exacerbation were airway infection in 45 patients (77.6%) and right heart failure in 13 patients (22.4%). All patients suffered from acute-on-chronic respiratory failure. The Acute Physiology and Chronic Health Evaluation (APACHE II) score, calculated on admission, was 18±4 (range, 9 to 24). The Glasgow coma scale (GCS) score was 14±1 ( Table 1) . The latest stable result in pulmonary function testing within a year before this admission was obtained in 29 patients (50.0%). The mean FVC and FEV1 were 1.24±0.44 L and 0.67±0.24 L, respectively, and the mean FEV1/FVC was 57.8±19.4%. For pharmacologic co-interventions, short acting beta-agonist was given for inhalation by 46 patients (79.3%), antibiotic agents were given to 47 patients (81.0%), diuretic agents were given to 22 patients (37.9%), and systemic corticosteroids were given to 3 patients (5.2%).
Blood gas exchange
Mean results of blood gas determinations 2 and 24 hours after admission are shown in Fig. 1 (Fig. 1) . However, no significant difference was found in blood gas improvement between the success group and failure group.
Clinical outcomes
The average duration of NIV use from the time of onset was 7.7 days (range, 1 to 53 days) in all patients. The mean settings used were IPAP of 12 cm H2O and EPAP of 4 cm H2O, with mean FiO2 of 31%. All patients in the study received bi-level positive-pressure ventilation. NIV led to successful avoidance of endotracheal intubation in 50 patients (86.2%); 49 were subsequently discharged from the hospital and 1 died of aspiration pneumonia after weaning from in- itial NIV therapy. Reasons for failed NIV were respiratory failure in 7 patients and refusal to continue NIV therapy in 1 patient. Of these 8 patients, 6 died without intubation due to a previous DNI order and 2 were intubated, 1 of whom subsequently died from respiratory failure (Fig. 2) .
T a b l e 1 . B a s e l i n e P a t i e n t Ch a r a c t e r i s t i c s
Factors related to success
There was no statistically significant difference in age, sex or cause of acute exacerbation between the success group and failure group. The 2 groups had approximately the same APACHE II scores (18.1 in the success group vs. 17.9 in the failure group) and APACHE II score could not be used to identify those who would require intubation or those with a higher risk of mortality. There was a statistically significant difference between the success and failure group in pH (7.28±0.07 vs. 7.23±0.05, p=0.0019). There was tendency for patients in the failure group to have a slightly higher PaCO2 (72.1±15.0 vs. 75.6±8.8 mmHg), but that difference was not statistically significant (p=0.1690). There were also no statistically significant differences between the groups in RR (28.8±6.3 vs. 28.6±6.1 breaths/min) or PaO2/FiO2 (259.8 vs. 273.1 mmHg). Body mass index (BMI) was significantly correlated with failure of NIV. The mean BMI in the success group was 18.5±3.9 kg/m 2 , whereas that in the failure group was 15.6±3.5 kg/m 2 (p= 0.0404). Hematological findings revealed significant differences between the success group and the failure group in blood leukocyte count (7,300±2,700 vs. 10,500±4,100/mm 3 , p=0.0344) and serum potassium (4.2±0.7 vs. 3.9±0.2 mEq/ L, p=0.0396). Plasma human atrial natriuretic peptide (hANP) was higher in the failure group, but the difference was not statistically significant (111.2±105.1 vs. 275.0± 244.5 pg/mL, p=0.0522). The latest stable result in pulmonary function testing within the year before this admission was obtained for 29 patients (26 in the success group and 3 in the failure group) and the difference between the success group and failure group was not statistically significant (Table 2).
Mortality
The length of the hospital stay among the surviving patients was 38.4±20.9 days (range, 7 to 88 days). Eight patients (13.8%) died during their hospital stay. Those patients had significantly lower pH on admission than the surviving patients (7.23±0.05 vs. 7.28±0.07, p=0.0158). PaCO2 was also higher on admission in the patients who died (79.4± 13.4 vs. 71.4±14.2 mmHg), but the difference was not statistically significant (p=0.0553). In looking at the cause of acute exacerbation, 6 of 45 patients (13.3%) whose acute exacerbation was caused by airway infection died and 2 of 13 patients (15.4%) in whom the cause was right heart failure died. The difference was not statistically significant. The mean survival time after admission was 14.0 months. The Kaplan-Meier survival plot for the entire study population is shown in Fig. 3 . The overall mortality rate at 1 year and 2 years was 48.3% (n=28) and 58.6% (n=34), respectively. Fourteen patients were previously treated by thoracoplasty with lung resection. Of those patients, none failed NIV ther-
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apy, whereas 8 of 44 patients (18.2%) who were not treated by thoracoplasty failed NIV therapy. The hospital mortality rate was also lower than in the patients who had been previously treated by thoracoplasty, 1/14 (7.1%) vs. 7/44 (15.9%), but the difference was not significant.
Discussion
This study which focused on patients with acute exacerbation of TB-seq, demonstrated that NIV was effective for such patients. In our study, 50 of 58 patients (86.2%) with acute exacerbation of TB-seq could be weaned from NIV and avoid endotracheal intubation, and were subsequently discharged from the hospital. This result is compatible with those of the numerous studies in patients with acute exacerbation of COPD, in which success rates in avoiding intubation have ranged from 69 to 93% (2-7). In a multicenter prospective randomized trial, Brochard et al found NIV therapy to be effective in patients with COPD exacerbations, with a success rate of 74.4% (32 of 43 patients) in NIV
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group (4) . Patients enrolled in the trial had a mean age of 71 years, and SAPS score calculated on admission was 12. In blood gas analysis, the mean pH and PaCO2 on admission were 7.24 and 70 mmHg, respectively. Confalonieri et al assessed risk stratification in 1,033 patients with COPD exacerbations and performed NIV therapy successfully in 797 patients (77.1%) (7). The mean age in that study was 69.5 and the mean pH and PaCO2 on admission were 7.28 and 80.4 mmHg, respectively. In our study, similarly severe patients were enrolled and the success rate of NIV therapy was comparable to the previous studies. Therefore, there was sufficient data to suggest that NIV therapy might be useful for acute exacerbation of TB-seq, and we concluded that NIV may be a viable option in the respiratory management of acute exacerbation of TB-seq.
TB-seq patients show restrictive or mixed ventilatory disorders and seldom show pure obstructive disorder. There are very few reports of NIV in patients with acute respiratory failure caused by restrictive thoracic diseases (RTD), especially TB-seq, perhaps because they make up only a small portion of patients presenting with acute respiratory failure. A few cases with RTD were included in several previous reports (8, (11) (12) (13) (14) (15) . Meduri et al evaluated the clinical application of NIV as first-line intervention in patients with hypercapnic and short-term hypoxemic acute respiratory failure (14) . Five of these patients had RTD. In all 5 patients (100%) gas exchange was improved and in 4 patients (80%) intubation could be avoided. Robino et al found that 20 patients with acute exacerbation of RTD, including 10 TB-seq cases, had a lower success rate on NIV than COPD (35% vs. 67%) (8) . However, we suppose the small patient number of the latter study makes their results inconclusive.
There were significant differences between the success and failure groups in pH, and there was a tendency for patients in the failure group to have a slightly higher PaCO2. Ambrosino reported that the severity of the episode of acute respiratory failure and the level of acidosis and hypercapnia during an initial trial of NIV have an influence on the likelihood for success with NIV, and may prove to be useful in deciding whether to continue with this treatment in patients with acute exacerbation of COPD (9) . In the present study, the immediate course was marked by rapid improvement in pH and PaCO2 over the first 2 hours. Moreover, there was significant improvement after 24 hours. These results agree with previous reports that demonstrated a significant improvement in physiologic measures during the first hour of NIV therapy (3, 4) .
In our study, BMI was significantly correlated with failure of NIV and the need for intubation (success group, 18.5±3.9 vs. failure group, 15.6±3.5 kg/m 2 ; p=0.0404). Hutter et al found that the one factor that did have statistical significance in the outcome of NIV for acute respiratory failure was BMI (29 vs. 23 kg/m 2 ; p=0.0167) (16) . In a large study of critically ill patients (17) , it has been shown that mortality was increased in underweight patients but not in overweight, obese, or severely obese patients. BMI may be a reflection of nutritional status and muscle mass, and lower muscle mass makes it more likely that a patient will become dependent on mechanical ventilation and less likely that the patient will have an effective cough. Our findings indicate that special attention and nutritional support should be given to acute exacerbation of TB-seq patients with lower BMI.
In our study, serum potassium was significantly lower in the failure group than in the success group. In an observa-F i g u r e 3 . S u r v i v a l a n a l y s i s o f p a t i e n t s a f t e r a c u t e e x a c e r b at i o n o f T B -s e q . b l e 2 . Co mp a r i s o n b e t we e n P a t i e n t s t h a t S u c c e e d e d a n d F a i l e d a tional study, it was reported that hypokalemia was independently correlated with mortality in patients with acute respiratory failure (18) . The reason may be that hypokalemia is a cause of muscle weakness that usually begins with the lower extremities and progresses to the trunk and upper extremities. If severe, hypokalemia can produce respiratory muscle weakness which may progress to respiratory insufficiency. Additionally, blood leukocytes were significantly increased in the failure group. However, the increased C-reactive protein level and the frequency of airway infection were not associated with the success of NIV therapy. These findings may suggest that a systemic increase in the absolute number of blood leukocytes is one of the important factors for successful continuity of NIV therapy, and that attention to NIV therapy is needed in TB-seq patients with marked leukocytosis. In this study, the mean survival time for all patients with acute exacerbation of TB-seq was 14.0 months. This is comparable to the results of previous studies of patients with acute exacerbation of COPD and sufficiently good to support the use of NIV in acute exacerbation of TB-seq (19) .
T a
In conclusion, we demonstrated that noninvasive positive pressure ventilation is effective in patients with acute exacerbation of TB-seq, as well as COPD. The risk factors for the failure of NIV are lower pH, body mass index, and serum potassium, and higher blood leukocyte count, on admission. These results should be taken into account when treating TB-seq patients with acute exacerbation with NIV.
